HUGE.CN - FSD Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.1000
-0.0050 (-4.76%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.1050
Open0.1000
Bid0.0950 x 0
Ask0.1000 x 0
Day's Range0.0950 - 0.1050
52 Week Range0.0950 - 0.9400
Volume1,989,758
Avg. Volume2,251,989
Market Cap138.845M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0150
Earnings DateMay 6, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Aura Announces Pharmadrug Operational & Investor Relations Update

    Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ, OTCQB:LMLLF) is pleased to provide an operational update on Pharmadrug Production GmbH (the “German Business” or “Pharmadrug”) and additional resources allocated to investor relations. Following Aura’s German operational update on June 5, 2019, Pharmadrug received its second, much larger shipment of medical cannabis from Netherlands at the end of June.

  • Business Wire

    FSD Pharma Appoints Larry Kaiser, MD, FACS, Dean, Lewis Katz School of Medicine at Temple University as Chairman of Its Scientific Advisory Board

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD” or the “Company”) today announced the appointment of Larry Kaiser, MD, FACS, Dean, Lewis Katz School of Medicine at Temple University and President & CEO of Temple Health System as Chairman of its Scientific Advisory Board (SAB). Dr. Kaiser replaces Dr. Charles Pollack, who has been placed on leave of absence.

  • GlobeNewswire

    Leo Acquisitions and CBx Brands Announce Letter of Intent for Proposed Qualifying Transaction

    Leo Acquisitions Corp. (LEQ-H.V) (“Leo” or the “Company”) and CBx Brands Inc. (“CBx”) are pleased to announce that they have entered into a letter of intent (the “LOI”), dated July 10, 2019, pursuant to which the Company and CBx have agreed to complete a transaction (the “Transaction”) that will result in a reverse take-over of the Company by the shareholders of CBx. It is intended that the Transaction will constitute the "Qualifying Transaction" of the Company as such term is defined in Policy 2.4 of the Corporate Finance Manual (the “Policy”) of the TSX Venture Exchange (the “TSXV”).

  • Market Exclusive

    FSD Pharma Acquires Prismic Pharmaceuticals

    FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) and US-based specialty R&D pharmaceutical company Prismic Pharmaceuticals finalized a deal for the acquisition of all of the issued and outstanding securities of Prismic by FSD Pharma. Under to the terms of a securities exchange agreement, FSD Pharma has acquired all outstanding common and preferred shares of […]The post FSD Pharma Acquires Prismic Pharmaceuticals appeared first on Market Exclusive.

  • Business Wire

    FSD Pharma Closes Deal to Acquire Prismic Pharmaceuticals

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD Pharma” or the “Company”) and Prismic Pharmaceuticals Inc. (“Prismic”), a US-based specialty R&D pharmaceutical company (the “Parties”), announced today that, on June 28, 2019, they finalized the acquisition by FSD Pharma of all of the issued and outstanding securities of Prismic (the "Transaction"). Pursuant to the terms of a previously-announced securities exchange Agreement, FSD Pharma has acquired all outstanding common and preferred shares of Prismic for an aggregate purchase price of approximately US$17.5 million (CAD$23.4 million based on an exchange rate of US$1 to CAD$1.3349), satisfied by the issuance of approximately 102.7 million Class B subordinate voting shares in the capital of FSD Pharma (each, an “FSD Share”) at a deemed price of CAD$0.2275 (US$0.1704) per FSD Share.

  • Market Exclusive

    FSD Pharma Gets License to Sell Cannabis for Medical Use

    FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced that its subsidiary FV Pharma has received its full sale for medical purposes license to sell cannabis under the Cannabis Act of Canada. The license, effective as of June 21, allows the FSD facility in Cobourg, Ontario, to supply and sell cannabis products, including dried and […]The post FSD Pharma Gets License to Sell Cannabis for Medical Use appeared first on Market Exclusive.

  • Business Wire

    FSD Pharma Receives Full “Sale for Medical Purposes” Cannabis License from Health Canada

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD” or the “Company”), announced today that its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”) has received its Full Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The latest amendment to the license, originally granted on April 18, 2019, allows the FSD facility in Cobourg, Ontario to supply and sell cannabis products, including dried and fresh cannabis to the medicinal use marketplace.

  • FSD Pharma Receives Full "Sale for Medical Purposes" Cannabis License from Health Canada
    CNW Group

    FSD Pharma Receives Full "Sale for Medical Purposes" Cannabis License from Health Canada

    TORONTO , June 24, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company"), announced today that its wholly-owned subsidiary FV Pharma Inc. ("FV Pharma") has received its Full Sale for Medical Purposes license to sell cannabis under the Cannabis Act ( Canada ). The latest amendment to the license, originally granted on April 18, 2019 , allows the FSD facility in Cobourg, Ontario to supply and sell cannabis products, including dried and fresh cannabis to the medicinal use marketplace. FV Pharma can now begin delivering cannabis to patients who hold prescriptions from authorized healthcare providers.

  • Newsfile

    FSD Pharma Continues to Add Expert Advisors Amid Buildout of Massive Facility -- CFN Media

    Seattle, Washington--(Newsfile Corp. - June 14, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF). The company has been focused on building out its board of directors and advisory board since becoming a full Canadian licensed producer earlier this year. After receiving its cultivation license in 2017, the company ...

  • Business Wire

    FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company"), today announced the appointment of James A. Datin and Robert J. Ciaruffoli, CPA to the Company’s Board of Directors. “It is an honor to welcome Jim Datin and Bob Ciaruffoli to the FSD Pharma Board of Directors,” said Dr. Raza Bokhari, Executive Co-Chairman and CEO. “The experience and expertise they both bring as c-level entrepreneurial executives, leaders and board members of impressive organizations will add tremendous value to FSD.

  • FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors
    CNW Group

    FSD Pharma Adds Biotech/LifeSciences Industry veteran James A. Datin and Robert J. Ciaruffoli, Former Chairman & CEO of Parente Beard/Baker Tilly to Board of Directors

    TORONTO , June 12, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company"), today announced the appointment of James A. Datin and Robert J. Ciaruffoli, CPA to the Company's Board of Directors. "It is an honor to welcome Jim Datin and Bob Ciaruffoli to the FSD Pharma Board of Directors," said Dr. Raza Bokhari, Executive Co-Chairman and CEO. "The experience and expertise they both bring as c-level entrepreneurial executives, leaders and board members of impressive organizations will add tremendous value to FSD.

  • Business Wire

    FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD” or the “Company”), is pleased to announce the addition of two distinguished cannabis researchers to the company’s Scientific Advisory Board (“SAB”). “It is with great pride that we welcome Dr. Ziva Cooper and Dr. Mallory Loflin to our Scientific Advisory Board. The board, which also includes Dr. Daniel Piomelli and Dr. Ryan Vandrey, is shaping into a very robust body of scientists and researchers under the leadership of my good friend Dr. Pollack and I commend him for his leadership.

  • FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board
    CNW Group

    FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board

    TORONTO , June 6, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company"), is pleased to announce the addition of two distinguished cannabis researchers to the company's Scientific Advisory Board ("SAB"). "It is with great pride that we welcome Dr. Ziva Cooper and Dr. Mallory Loflin to our Scientific Advisory Board.

  • Newsfile

    FSD Pharma Brings in World-Renowned Experts to Build Bioscience Division -- CFN Media

    Seattle, Washington--(Newsfile Corp. - June 4, 2019) - CFN Media Group ("CFN Media"), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF). The company may be known for having one of the largest cultivation footprints in the world with nearly 70 acres and four million square feet, but it's equally focused on advancing the science behind ...

  • Dr. Raza Bokhari, FSD Pharma Executive Co-Chairman and CEO to Participate in Biotech-Focused Panel at the 2019 BIO International Convention
    CNW Group

    Dr. Raza Bokhari, FSD Pharma Executive Co-Chairman and CEO to Participate in Biotech-Focused Panel at the 2019 BIO International Convention

    Dr. Raza Bokhari, FSD Pharma Executive Co-Chairman and CEO to Participate in Biotech-Focused Panel at the 2019 BIO International Convention

  • Business Wire

    FSD Pharma Names Raza Bokhari, M.D. as Permanent CEO

    The Board of Directors of FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company"), unanimously voted Raza Bokhari, M.D., Executive Co-Chairman of the Board, as permanent Chief Executive Officer. Dr. Bokhari has served as interim CEO of the Company since February.

  • FSD Pharma Congratulates High Tide on the Resumption of Retail Cannabis Licensing by AGLC in Alberta
    CNW Group

    FSD Pharma Congratulates High Tide on the Resumption of Retail Cannabis Licensing by AGLC in Alberta

    TORONTO , May 31, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company") would like to congratulate High Tide Inc. (CSE:HITI) (HITIF) (2LY.F) ("High Tide") on the recent announcement from Alberta Gaming, Liquor and Cannabis lifting the moratorium on issuing cannabis licenses and accepting license applications. The announcement is an encouraging sign of steadily improving cannabis supply levels in Alberta and is a positive step for companies like High Tide that have numerous stores ready and waiting to retail cannabis products. As a strategic investor in High Tide, FSD Pharma is pleased to see changes that will support the continued growth and success of the cannabis industry as well as the companies in which it is invested.

  • Edward Brennan, Jr., M.D., FACS to Lead FSD Pharma BioSciences Division
    CNW Group

    Edward Brennan, Jr., M.D., FACS to Lead FSD Pharma BioSciences Division

    TORONTO , May 28, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company"), today announced the appointment of pharmaceutical industry leader, Edward J. Brennan, Jr. , M.D., FACS, as President of its biosciences division. Dr. Brennan has more than 25 years' experience in leadership roles at major pharmaceutical companies and clinical research organizations.

  • FSD Pharma Welcomes All-Star Lineup of Cannabis Researchers to Scientific Advisory Board
    CNW Group

    FSD Pharma Welcomes All-Star Lineup of Cannabis Researchers to Scientific Advisory Board

    TORONTO , May 20, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company"), is pleased to announce that three eminent cannabis researchers have joined the company's Scientific Advisory Board ("SAB"). "We are honored to welcome Daniele Piomelli , Ph.D., Ryan Vandrey , Ph.D. and David Casarett , MD, MA to our Scientific Advisory Board," said Dr. Raza Bokhari , FSD Executive Co-Chairman & Chief Executive Officer.